PolyPid stock (US70450B1035): NDA submission advances D-PLEX100 toward FDA review

PolyPid transitioned to regulatory review phase for its lead drug D-PLEX100 on May 13, 2026, initiating rolling NDA submission to the FDA while finalizing U.S. commercial partnerships.

PolyPid Ltd (Nasdaq: PYPD) reached a critical regulatory milestone on May 13, 2026, as the clinical-stage biotechnology company advanced its lead product candidate D-PLEX100 into the FDA review phase. The company initiated a rolling new drug application (NDA) submission on March 30, 2026, marking a transition from late-stage clinical development toward potential regulatory approval and commercialization, according to MarketBeat as of May 13, 2026.

D-PLEX100 is designed to prevent surgical site infections in abdominal colorectal surgery, addressing a significant clinical need in the surgical care market. Chief Executive Officer Dikla Czaczkes Akselbrad outlined the company's dual priorities: advancing D-PLEX100 toward potential FDA approval and finalizing a U.S. strategic partnership intended to support a commercial launch in the first quarter of 2027, according to earnings call highlights as of May 13, 2026.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PolyPid Ltd
• Sector/industry: Biotechnology, drug delivery systems
• Headquarters/country: Israel
• Core markets: United States (primary focus)
• Key revenue drivers: D-PLEX100 regulatory approval and commercialization
• Home exchange/listing venue: Nasdaq (PYPD)
• Trading currency: USD

PolyPid: polymer-based drug delivery innovation

PolyPid Ltd develops long-acting, polymer-based drug delivery technologies designed to enhance therapeutic performance at the point of care. The company's proprietary platform enables controlled release of active pharmaceutical ingredients, with D-PLEX100 representing the lead clinical application. Unlike many small biotechnology firms, PolyPid manufactures D-PLEX100 at its own facility, avoiding reliance on third-party contract manufacturing organizations (CMOs). The manufacturing site has passed four consecutive Good Manufacturing Practice (GMP) inspections, demonstrating operational readiness for commercial production, according to TipRanks as of May 2026.

Q1 2026 financial results and regulatory progress

PolyPid reported a net loss of $7.7 million for the first quarter of 2026, representing an improvement from the prior-year period. The company beat earnings expectations, reporting an EPS of negative $0.35 versus consensus expectations of negative $0.47, according to InsiderMonkey earnings transcript as of May 2026. General and administrative expenses increased to $1.6 million from $1.2 million in the same quarter last year. Cash reserves declined to $10.9 million as of March 31, 2026, from $12.9 million in the prior-year period, reflecting ongoing investment in regulatory and commercial preparation activities.

A significant positive development emerged when PolyPid received a small business waiver from the FDA for the Prescription Drug User Fee Act (PDUFA) fee, saving approximately $4.3 million. This waiver substantially reduces the financial burden associated with NDA submission and review, according to GuruFocus as of May 13, 2026.

Commercial partnership and market launch timeline

PolyPid is in late-stage discussions for a U.S. strategic partnership focused on finalizing definitive agreement terms. The partnership is intended to support the commercial launch of D-PLEX100 in the first quarter of 2027, contingent on FDA approval. This timeline aligns with the rolling NDA submission process, which allows the company to submit sections of the application sequentially rather than all at once, potentially accelerating the overall review timeline.

Conclusion

PolyPid's advancement to the regulatory review phase for D-PLEX100 represents a pivotal transition for the clinical-stage biotechnology company. The rolling NDA submission, combined with the FDA's small business waiver and ongoing commercial partnership discussions, positions the company for potential product approval and market entry in 2027. While cash reserves remain a consideration for investors, the company's operational readiness and regulatory progress suggest meaningful near-term catalysts. US investors tracking surgical infection prevention therapies and early-stage biotech regulatory milestones should monitor upcoming FDA review timelines and partnership announcements.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.